Merck & Co Inc (XSGO:MRK)
$ 125.34 0 (0%) Market Cap: 327.47 Bil Enterprise Value: 356.07 Bil PE Ratio: 143.66 PB Ratio: 8.11 GF Score: 84/100

Merck & Co Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 17, 2020 / 02:00PM GMT
Release Date Price: $81.87
Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD

Hi, I am Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Merck.

Despite the impact COVID-19 has had on the industry, the underlying revenue growth for Merck's key products underscore that its oncology, vaccines, animal health and select hospital specialty care products as well as margin expansion opportunities remain underappreciated. Therefore, multiple expansion should drive Merck's shares higher as customer access gets better despite the ongoing pandemic and earnings visibility improves beyond the KEYTRUDA patent cliff in 2028.

Therefore, we're very excited to have with us Merck's Chief Marketing Officer, Mike Nally, today to discuss the future direction of the company.

Questions & Answers

Louise Alesandra Chen
Cantor Fitzgerald & Co., Research Division - Senior Research Analyst & MD

Mike, it's not too early anymore to start thinking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot